Nilotinib Viatris (Nilotinib)

Nilotinib works by selectively binding to the ATP‑binding site of the BCR‑ABL tyrosine kinase, blocking its activity. This inhibition stops downstream signaling that drives uncontrolled proliferation of leukemic cells, leading to reduced tumor growth and increased apoptosis of abnormal cells.

The specific dose of Nilotinib Viatris is determined by the prescribing physician based on the patient’s clinical condition, disease stage, and individual tolerance. Dosing regimens are individualized and should follow the prescriber’s instructions and local regulatory guidelines.

The safety of nilotinib during pregnancy or lactation has not been established. It is classified as pregnancy category unknown, and the drug may pose risks to the fetus or infant. Women of child‑bearing potential should use effective contraception, and breastfeeding is generally not recommended while on therapy.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nilotinib belongs to the second‑generation tyrosine‑kinase inhibitor class, offering higher potency against BCR‑ABL than first‑generation agents like imatinib. It is often selected for patients who need a more robust molecular response or who have resistance/intolerance to earlier TKIs, though individual choice depends on clinical factors.

Nilotinib tablets should be stored at ambient temperature, below 25 °C, in the original blister pack or container. Keep the product away from moisture, direct sunlight and excessive heat to maintain stability and potency throughout its shelf life.

Nilotinib Viatris is taken orally, usually as whole tablets with a low‑fat meal. Patients should swallow the tablets whole with water and follow the dosing schedule prescribed by their healthcare provider, ensuring consistent timing to maintain steady drug levels.

Serious risks include cardiovascular events such as arterial occlusive disease, QT‑interval prolongation leading to arrhythmias, severe liver injury, pancreatitis, and tumor lysis syndrome. Patients should be monitored regularly for these complications, and therapy should be discontinued if life‑threatening events occur.

Nilotinib is contraindicated in patients with a known hypersensitivity to nilotinib or any of its excipients, and in those with a pre‑existing prolonged QT interval. Caution is also advised for individuals with significant cardiac disease, uncontrolled infections, or severe hepatic impairment.